TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06163963

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Sentinel Lymph Node Mapping With Double Tracer and Double Injection Sites in Early-Stage Endometrium Cancer
Description: This is a single arm interventional prospective study. Sentinel lymph node detection rate of the tracer injected in cervix (ICG- indocyanine green) before operation and the second tracer injected in uterine fundal subserosa (sterile charcoal black) at the start of operation are investigated. It is anticipated that additional tracer used in the uterine serosa may overcome the insufficiency (or increase the detection rate) of the standard single tracer injected in cervix for detection rate of sentinel lymph nodes, especially in paraaortic sentinel lymph nodes.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: charcoal injection to uterus to map sentinel lymph nodes
Description: During surgery for endometrial cancer, charcoal injection to uterus to map sentinel lymph nodes in para aortic area besides the classic ınjection of indocyanine green for pelvic sentinel lymph node mapping.
Study: NCT05837338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BXP154
Description: BXP154 will be self-administered topically following wound induction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BXP154
Description: BXP154 will be self-administered topically following wound induction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BXP154
Description: BXP154 will be self-administered topically following wound induction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BXP154
Description: BXP154 will be self-administered topically following wound induction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be self-administered topically following wound induction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be self-administered topically following wound induction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be self-administered topically following wound induction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be self-administered topically following wound induction
Study: NCT06146257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLB-001
Description: Administered orally according to the assigned treatment schedule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLB-001
Description: Administered orally according to the assigned treatment schedule
Study: NCT05012345

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Below Elbow cast
Description: below-elbow cast ( 4 or 6 weeks )

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Below Elbow cast
Description: below-elbow cast ( 4 or 6 weeks )
Study: NCT06495983

Intervention type: DEVICE
Intervention: dynamic microdialysis sampling
Description: Included patients will perform 24-hour dynamic microdialysis sampling from subcutaneous tissue fluid of the lower abdomen, applying the U-Rhythm sampler. Simutaneous measurements of blood pressure, glucose, and registration of activity level, meals and sleep pattern during microdialysis sampling may be performed. Microdialysis sampling will be performed during various conditions: during daily life activities, during saline infusion suppression testing and during dexamethasone suppression testing. Repeated sampling may be performed post treatment.
Study: NCT06485024

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Modeling Resin
Description: it is the application of Modeling liquid to make easier manipulation and sculpting the composite veneer and reflect on its physical properties and clinical performance

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modeling Resin
Description: it is the application of Modeling liquid to make easier manipulation and sculpting the composite veneer and reflect on its physical properties and clinical performance
Study: NCT05608421

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 1MoreStep
Description: Cognitive behavioral intervention to reduce HIV and IPV stigma.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 1MoreStepControl
Description: This is an equal attention control group.
Study: NCT05101174

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Intervention Group (IIG)
Description: The IIG attends 150 min exercise per week, which consists of one 90-min trainer-supervised session and multiple online sessions for 6 months. Each session consists of (1) warm-up, (2) resistance exercise and flexibility exercise, (3) resistance exercise and coordinative exercise from the Eastern exercise perspective, (4) social interaction exercise, and (5) cool-down and meditation.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control Group
Description: The Control Group is informed to maintain their lifestyles and invited to attend one 60-min online educational course per week. The participants are required to provide their physical activity behavior once every month for 6 months (6 times).
Study: NCT05372718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant non-immunogenic staphylokinase (Fortelyzin®)
Description: lyophilisate for preparation a solution

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgical methods of treatment
Description: Endovascular intervention, open surgery and/or bypass surgery in accordance with the current National Guidelines
Study: NCT05961553

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Counseling session
Description: The counseling session on physical activity was carried out individually, six weeks after starting the respiratory rehabilitation program, with an average duration of 30 minutes, based on the guidelines of the Living Well with COPD program. The main objective of the session was: to help the participant and family members to increase physical activity levels and their integration in the long term and as secondary objectives; reinforce the importance and benefits of physical activity in the management of the health condition/symptoms; plan daily/weekly moments of physical activity; define daily goals (physical activity time/sitting time) attainable for each participant; integrate family members/companions into the user's physical activity plan; clarify doubts of the user/relative about the theme.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary Reabilitation
Description: The program comprises a hospital group exercise program, twice a week, on alternate days, for 1h30 to 2h, each session.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary Reabilitation
Description: The program comprises a hospital group exercise program, twice a week, on alternate days, for 1h30 to 2h, each session.
Study: NCT05826483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Almonertinib
Description: Almonertinib Mesilate Tablets
Study: NCT05379179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: This study will compare patient-reported pain scores after receiving either ketamine or fentanyl for the treatment of acute pain due to a rattlesnake bite.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: This study will compare patient-reported pain scores after receiving either ketamine or fentanyl for the treatment of acute pain due to a rattlesnake bite.
Study: NCT06398210

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Exercise Therapy Approach (BETY)
Description: Cognitive Exercise Therapy Approach (BETY) BETY includes mind-body interaction information management, pain management strategies, mood information management through dance therapy/authentic movement, and sexuality information management. BETY first session; After meeting the patient and completing the evaluations, it consists of the steps of analysis of the person's problem, selection of exercise for this problem, replacement of the exercise in function, pain management, and recovery agreement. The basic exercise model used in BETY is function-oriented trunk stabilization exercises. Patients are given information about the 5 features of trunk stabilization (neck, shoulder, rib cage, lumbopelvic region postures, and respiratory control), visual imagery, and their control.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Exercise Therapy Approach (BETY)
Description: Cognitive Exercise Therapy Approach (BETY) BETY includes mind-body interaction information management, pain management strategies, mood information management through dance therapy/authentic movement, and sexuality information management. BETY first session; After meeting the patient and completing the evaluations, it consists of the steps of analysis of the person's problem, selection of exercise for this problem, replacement of the exercise in function, pain management, and recovery agreement. The basic exercise model used in BETY is function-oriented trunk stabilization exercises. Patients are given information about the 5 features of trunk stabilization (neck, shoulder, rib cage, lumbopelvic region postures, and respiratory control), visual imagery, and their control.
Study: NCT04446637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination (2 inhalations) via pMDI
Description: Ipratropium/Levosalbutamol 20 mcg/50 mcg Aerosol Inhalation, Suspension 2 inhalations in the morning (single day)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salbutamol 100 mcg Inhaler (2 inhalations) + Ipratropium 20 mcg Inhalation Aerosol (2 inhalations) Free Combination via MDI
Description: Salbutamol 100 mcg Inhaler, 2 inhalations + Ipratropium 20 mcg Inhalation Aerosol,2 inhalations in the morning (single day).
Study: NCT04938960

Intervention type: DIAGNOSTIC_TEST
Intervention: blood draw
Description: blood will be drawn at pre-operation, between 2 weeks and 3 months, between 3-11 months (optional; we will collect a sample if the patient returns to Mayo Clinic for any other non-study related visit), and between 12-18 months post-operatively.

Intervention type: DIAGNOSTIC_TEST
Intervention: blood draw
Description: blood will be drawn at pre-operation, between 2 weeks and 3 months, between 3-11 months (optional; we will collect a sample if the patient returns to Mayo Clinic for any other non-study related visit), and between 12-18 months post-operatively.
Study: NCT05421949

Intervention type: OTHER
Intervention: Exercise group
Description: Incremental Shuttle Walking Test
Study: NCT05083351

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MightySat
Description: Noninvasive pulse oximeter
Study: NCT05604846

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: ProPrems
Description: The intervention product, commercially known as ProPrems®, is a combination of (one billion freeze-dried bacteria per 0.5 g in a maltodextrin base powder: Bifidobacterium infantis Bb-02 (DSM 33361) 300 million, Bifidobacterium lactis (BB-12®) 350 million, and Streptococcus thermophilus (TH-4®) 350 million will be given daily once to eligable infants born extremly preterm (\<28weeks of gestation) once they tolerate 3ml of enterla feeds until the age of 34 weeks of gestation.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ProPrems
Description: The intervention product, commercially known as ProPrems®, is a combination of (one billion freeze-dried bacteria per 0.5 g in a maltodextrin base powder: Bifidobacterium infantis Bb-02 (DSM 33361) 300 million, Bifidobacterium lactis (BB-12®) 350 million, and Streptococcus thermophilus (TH-4®) 350 million will be given daily once to eligable infants born extremly preterm (\<28weeks of gestation) once they tolerate 3ml of enterla feeds until the age of 34 weeks of gestation.
Study: NCT05620433

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Joint Effort
Description: The Joint Effort intervention is available in the form of an iPhone mobile application (running on iOS 13 and higher) in French language. It aims to support young adults in school who have used cannabis in the past month into taking action on their cannabis use.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Brief normative feedback and standard information
Description: The brief normative feedback is based on the frequency of cannabis use. Participants will also be offered basic reliable non-personalized information on lower-risk cannabis use in the form of official public websites.
Study: NCT06486103

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MetSheFlora - Vaginal Health
Description: Take one slow-release capsule twice a day, after meal.
Study: NCT06423365

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Statin Management (VSM)
Description: VSM is a web-based decision aid to help manage statin therapy after experiencing muscle pain perceived to be caused or worsened by their statin therapy. The introduction will feature a brief explanation of the tool and what they can expect. The modules are:~1. General education (lipids, heart disease, medications)~2. Side effects (causes, diagnosis).~3. Statin modifications. VSM will guide patients to understand their lipid-lowering options, particularly their statin options that may best match patients' stated preferences.~4. ASCVD risk \& statin benefit. Finally, the VSM experience will end by providing the patient with a summary of the results of their use of the tool, which can be used during discussions with their healthcare provider. The information gathered from the VSM will remain confidential and will not be disclosed to anyone other than the patient.
Study: NCT06275451

Intervention type: OTHER
Intervention: Semi-structured interview
Description: Semi-structured interview on emotional regulation and administration of questionnaires lasting approximately 2 hours.
Study: NCT05544240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SV-101
Description: SV-101 is intended to overcome the complex and multifactorial nature of the mechanisms mediating tumor immune evasion, by the use of a combination of therapeutic agents that elicit multiple immuno-pharmacologic effects.
Study: NCT05951400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dydrogesterone Tablets
Description: used for pituitary suppression in ICSI cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetrorelix
Description: GnRH antagonist for pituitary suppression
Study: NCT06308952

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 20mg
Description: Eligible subjects screened will enter the pretreatment period (days 1 to 4) and be randomly assigned to the trial group (oral atorvastatin) or the control group (placebo) to start receiving the trial drug (20mg, qd). At the same time, the patient was started on basic dual antibody therapy (aspirin 75mg qd + clopidogrel 75mg qd/ticagrelor 45mg bid).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin 20mg
Description: Eligible subjects screened will enter the pretreatment period (days 1 to 4) and be randomly assigned to the trial group (oral atorvastatin) or the control group (placebo) to start receiving the trial drug (20mg, qd). At the same time, the patient was started on basic dual antibody therapy (aspirin 75mg qd + clopidogrel 75mg qd/ticagrelor 45mg bid).
Study: NCT06039839

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Closure of the donor area after CTG harvesting without the use of collagen matrix
Description: 1. Incision the mucosa at the alveolar ridge, mucosal-periosteal flap elevation, placement of the dental implant~2. Harvesting of free connective tissue graft from the maxilla tuberosity area and it's fixation to the vestibular mucosal-periosteal flap, tight suturing of the wound in the recipient area~3. Suturing of the wound in the donor site.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Closure of the donor area after CTG harvesting with collagen matrix
Description: 1. Incision the mucosa at the alveolar ridge, mucosal-periosteal flap elevation, placement of the dental implant~2. Harvesting of free connective tissue graft from the maxilla tuberosity area and it's fixation to the vestibular mucosal-periosteal flap, tight suturing of the wound in the recipient area~3. Adaptation of sterile collagen matrix to the donor site~4. Suturing of the wound in the donor site
Study: NCT05892224

Intervention type: PROCEDURE
Intervention: Laparoscopic sleeve gastrectomy
Description: Obese patients of different subtypes were all expected to undergo bariatric surgery

Intervention type: PROCEDURE
Intervention: Laparoscopic sleeve gastrectomy
Description: Obese patients of different subtypes were all expected to undergo bariatric surgery

Intervention type: PROCEDURE
Intervention: Laparoscopic sleeve gastrectomy
Description: Obese patients of different subtypes were all expected to undergo bariatric surgery

Intervention type: PROCEDURE
Intervention: Laparoscopic sleeve gastrectomy
Description: Obese patients of different subtypes were all expected to undergo bariatric surgery
Study: NCT06251167

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lateral wedge insoles (LWIs)
Description: Participants will be asked to wear these insoles in their own shoes for at least 5 hours per day for a period of 3 months. The LWIs will be constructed via 3D printing using a material of uniform density made to the length of the participant's feet, and will incorporate a 6 degree wedge along the lateral edge.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lateral wedge plus custom arch support (LWAS)
Description: Participants will be asked to wear these insoles in their own shoes for at least 5 hours per day for a period of 3 months. These insoles will be designed based on an innovative tablet-based app designed by industry partner Kintec Footlabs, who will be the provider of the insoles for this project. Using the high-fidelity 3D scanning tool available (Apple's True Depth sensor), the Epitek Self-Scanner app captures tens of thousands of 3D data points within a single 1-second capture, and then uploads this foot data to a secure patient record system that is used for insole fabrication. The LWAS insoles will be comprised of variable density material (more dense laterally than medially) and milled directly to produce a full-length shell. The 6 degree wedge will be incorporated along the full lateral length of the insoles.
Study: NCT05544526

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GD2 CAR T cells
Description: Infusion with: GD2 CAR T-cells
Study: NCT06525298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EIS-12656
Description: EIS-12656 tablets given daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EIS-12656
Description: EIS-12656 tablets given daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EIS-12656
Description: EIS-12656 tablets given daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EIS-12656
Description: EIS-12656 tablets given daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: as per USPI/SmPC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: as per USPI/SmPC
Study: NCT05541926

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: e-Connect
Description: Implementation of the e-Connect system
Study: NCT05403606

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GASPARD®
Description: Spinal cord injured patient with the connected electronic seat pressure measurement device (GASPARD®), a traditional follow-up and having received therapeutic education at the end of the treatment
Study: NCT04723511

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Global Postural Re-education
Description: treatment techniques include corrective exercises both local and global to correct forward head posture.~first session will be to educate participants on the treatment sequence. This will be a session of Kendall's exercises as described below. This will followed be by performing GPR techniques of Anterior Chain stretch in the supine frog-like position for 20 minutes followed by posterior chain stretch against the wall for another 20 minutes. This is repeated in the first 6 sessions. Starting from the seventh session the time of holding each position is decreased to 15 minutes and a third position (standing against the wall) is introduced and performed for 15 minutes. Starting from the eighth session fourth position of sitting on the floor position is introduced and performed for another 15 minutes. total of a session will then take about 90 minutes.~Pre-treatment diaphragmatic release and deep breathing exercises are applied at the beginning of each session

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kendall exercises
Description: exercises that correct upper crossed syndrome:~The treatment sequence will be:~a) Strengthen deep Cervical Flexors via Chin tucks. Repetition will be repeated 10 times for 5 sets.~(b) Stretching the cervical extensors. This is held for 1 minute and repeated 5 times.~(c) Strengthening shoulder retraction. Repetition will be repeated 10 times for 5 sets.~(d) Stretching the pectoralis muscle. This is held for 1 minute and repeated 5 times.~Exercises will be progressed as the sessions develop.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kendall exercises
Description: exercises that correct upper crossed syndrome:~The treatment sequence will be:~a) Strengthen deep Cervical Flexors via Chin tucks. Repetition will be repeated 10 times for 5 sets.~(b) Stretching the cervical extensors. This is held for 1 minute and repeated 5 times.~(c) Strengthening shoulder retraction. Repetition will be repeated 10 times for 5 sets.~(d) Stretching the pectoralis muscle. This is held for 1 minute and repeated 5 times.~Exercises will be progressed as the sessions develop.
Study: NCT06126614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine Gluconate
Description: 0.05% chlorhexidine gluconate solution for irrigation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine Gluconate
Description: 0.05% chlorhexidine gluconate solution for irrigation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin Hydrochloride
Description: 2 grams of topical vancomycin hydrochloride added to the wound

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin Hydrochloride
Description: 2 grams of topical vancomycin hydrochloride added to the wound

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin Hydrochloride
Description: 2 grams of topical vancomycin hydrochloride added to the wound

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Povidone-Iodine
Description: 0.35% povidone-iodine solution for irrigation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Povidone-Iodine
Description: 0.35% povidone-iodine solution for irrigation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: saline for irrigation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline
Description: saline for irrigation